CHOP and Abu Dhabi Partner to Advance Rare Disease Gene Editing
Event summary
- Children's Hospital of Philadelphia (CHOP) signed a MoU with the Department of Health – Abu Dhabi to advance gene editing for rare diseases.
- The collaboration will provide specialized training to Abu Dhabi clinician-scientists in innovative gene editing approaches.
- CHOP's expertise in personalized, liver-directed gene editing will be leveraged to build local capabilities in Abu Dhabi.
- Nearly one million genomes sequenced through the Emirati Genome Programme will support population-scale genomic insights.
The big picture
This partnership combines CHOP's leading gene editing capabilities with Abu Dhabi's comprehensive genomics ecosystem, aiming to accelerate precision medicine for rare diseases. The collaboration underscores a broader trend of international partnerships in biotechnology to address complex genetic conditions at scale. With nearly one million genomes sequenced, Abu Dhabi is positioning itself as a hub for genomic research and clinical innovation.
What we're watching
- Execution Risk
- How CHOP will integrate its gene editing expertise with Abu Dhabi's genomics ecosystem.
- Regulatory Dynamics
- Whether the collaboration can navigate regulatory frameworks in both the US and UAE.
- Market Expansion
- The pace at which Abu Dhabi can develop advanced therapies for rare diseases prevalent in the region.
Related topics